<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629757</url>
  </required_header>
  <id_info>
    <org_study_id>CSNO2015001</org_study_id>
    <nct_id>NCT02629757</nct_id>
  </id_info>
  <brief_title>A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas</brief_title>
  <acronym>β-elemene</acronym>
  <official_title>A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to help determine whether β-elemene as maintain treatment for
      complete remission patients of newly diagnosed malignant gliomas following standard
      treatment, is able to delay tumor growth, or impact how long people with newly diagnosed
      high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to help determine whether β-elemene as maintain treatment for
      complete remission patients of newly diagnosed malignant gliomas following standard
      treatment, is able to delay tumor growth, or impact how long people with newly diagnosed
      high-grade glioma. β-elemene will be given 600mg/d,d1-14,q28 days for 6 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over-all survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>β-elemene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β-elemene</intervention_name>
    <description>β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles</description>
    <arm_group_label>β-elemene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Page 3 of 4 [DRAFT] - Arms Assigned Interventions

               -  Temodar Experimental: temozolomide +α-IFN Four weeks after radiotherapy, patients
                  will be received 6 cycle of temozolomide plus α-IFN α-IFN： 3mIU (3million)
                  Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study
                  cycle and 200 mg/m^2 daily of subsequent cycles Drug: Temozolomide dosed at 200
                  mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated
                  every 28 days

        Other Names:

        • Temodar Drug: α-IFN 3mIU (3million) D1，3，5

        Other Names:

        Minimum Age: 18 Years Maximum Age: 75 Years Gender: Both Accepts Healthy Volunteers?: No

        Criteria: Inclusion Criteria:

          -  Age: 18 years to 75 years

          -  complete remission patients of newly diagnosed WHO III-IV glioma following standard
             treatment

          -  Karnofsky Performance Score ≥ 60

          -  Adequate bone marrow, liver and renal function

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent

          -  anticipating survival ≥2 months

        Exclusion Criteria:

          -  Refusal to participate the study

          -  Known hypersensitivity or contraindication to temozolomide

          -  Incompletely radiation

          -  Pregnant or lactating females

          -  Malignant tumor other than brain tumor

          -  Contraindicated for MRI examination

          -  Unable to comply with the follow-up studies of this trial

          -  Purulent and chronic infected wounds

          -  Uncontrolled psychotic disorders or epilepsy

          -  progression disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-ping CHEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong-ping CHEN</last_name>
    <phone>+86-20-87343310</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengceng Guo</last_name>
    <phone>+86-20-87343890</phone>
    <email>guochch@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-ping Chen</last_name>
      <phone>+86-20-87343310</phone>
    </contact>
    <contact_backup>
      <last_name>Chengcheng Guo</last_name>
      <phone>+86-20-87343890</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>High-grade glioma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>β-elemene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

